Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AR-2475
- Development stage
- Unknown
- Lead developer
- Alcon
- Modality
- Implantable Hydrogels → Hydrogel Systems → Drug Delivery Systems, Small Molecules, Implantable Devices → Device-based Delivery → Drug Delivery Systems
- Administration
- Intracameral
01
Overview
AR-2475 is a sustained-release (SR) intracameral implant containing a potent Rho kinase (ROCK) inhibitor, currently under development for the treatment of open-angle glaucoma and ocular hypertension. Developed by Aerie Pharmaceuticals (now a subsidiary of Alcon), the implant is designed to provide continuous intraocular pressure (IOP) reduction over several months, addressing the significant challenge of patient non-compliance with daily topical eye drops. The active pharmaceutical ingredient inhibits both ROCK1 and ROCK2 isoforms, which enhances aqueous humor outflow through the trabecular meshwork—the primary drainage pathway of the eye—and may also reduce aqueous humor production and episcleral venous pressure. This long-acting formulation utilizes a biodegradable polymer matrix to deliver the drug directly to the target tissues in the anterior chamber.
- Other names
- ROCK inhibitor SR implant
02
Targets
ROCK1 (Rho-associated coiled-coil containing protein kinase 1)ROCK2 (Rho-associated coiled-coil containing protein kinase 2)
Beyond the preview
Go deeper on AR-2475.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AR-2475.